Sartorius (SRT) investor relations material

Strategic direction, innovation, and market positioning

• Focus on maintaining pure-play leadership in biopharma, expanding into advanced therapies, digital solutions, and process intensification, while leveraging core strengths and emerging technologies.

• Emphasis on innovation through targeted M&A, partnerships, and internal development, especially in AI, automation, and advanced cell models.

• Maintain leadership in single-use technologies and process intensification, strengthening bioanalytics and cell analytics offerings.

• Strategic levers include portfolio innovation, customer experience, and operational excellence, with clear KPIs and a commitment to above-market, profitable growth.

• Address evolving biopharma R&D needs, including predictive, human-relevant testing solutions and advanced therapy platforms.

Market outlook, trends, and growth drivers

• Bioprocess Solutions market expected to grow 8%-10%, Lab Products & Services at 4%-6%, with group growth targeted at 8%-11% from 2027; aims to outpace market by 100–200 basis points.

• Biologics projected to reach 57% of global pharma sales by 2030, with advanced therapies and new modalities representing ~50% of pipeline molecules.

• Single-use technologies, process intensification, and automation are key growth drivers, with >85% penetration in clinical settings.

• Market fundamentals supported by demographic trends, increased drug approvals, and demand for efficiency and automation.

• Regulatory shifts and technological advances (AI, automation) create new business opportunities in lab workflows and toxicity testing.

Financial guidance and operational performance

• Group targets 8–11% organic sales revenue growth per year from 2027, with EBITDA margin expansion of 50–200 basis points annually starting 2027.

• 2026 is a transition year, with normalization and full alignment to midterm guidance expected by 2027; sales revenue growth of 5–9% and EBITDA margin slightly above 30%.

• Margin improvement supported by operational leverage, cost discipline, automation, and a shift to higher-value consumables.

• CapEx to normalize to ~9% of turnover by 2028 after major investments, with strong cash generation and disciplined capital deployment to support deleveraging.

• Efficiency program aims for €100m cost savings in 2025, with ongoing digital and lean initiatives to drive further margin improvements.